Peptides in Perimenopause: A Physician's Cautiously Curious Perspective
Written and edited by Sarah Bonza MD, MPH, FAAFP, MSCP, DipABLM, NBC-HWC
Peptides are not a replacement for foundational health. They are not a shortcut, not a magic solution, and certainly not appropriate for everyone.
As a board-certified family physician and Menopause Society Certified Practitioner, I've built my practice on evidence-based medicine. I prescribe FDA-approved hormone therapy, recommend lifestyle interventions backed by robust clinical trials, and ground every recommendation in peer-reviewed research. So when patients began asking me about peptides—compounds buzzing through wellness circles with promises of enhanced healing, improved body composition, and anti-aging benefits—I'll admit my initial reaction was skepticism.
But curiosity is also part of medicine. As I've dug deeper into the research, I've found a more nuanced picture—one that warrants neither wholesale dismissal nor enthusiastic endorsement. This blog represents my honest assessment as a physician navigating this emerging space, with all its promise and its very real limitations.
Let me be clear from the outset: peptides are not a replacement for foundational health. They are not a shortcut, not a magic solution, and certainly not appropriate for everyone.
In my practice, I only consider peptides as a potential addition after we've optimized hormonal health, addressed nutritional deficiencies, regulated nervous system strain, and established consistent lifestyle habits, including strength training, quality sleep, and stress reduction. Peptides, when appropriate, may enhance gains—not replace the work required to achieve them.
Peptides are not a replacement for foundational health. They are not a shortcut, not a magic solution, and certainly not appropriate for everyone.
What Are Peptides?
Peptides are short chains of amino acids—typically between 2 and 50 amino acids linked together. They function as signaling molecules in the body, influencing processes ranging from tissue repair to hormone secretion to immune function. Our bodies naturally produce thousands of peptides that regulate critical physiological functions.
The peptides discussed in wellness and anti-aging contexts are either synthetic versions of naturally occurring compounds or laboratory-designed variants intended to mimic or enhance specific biological effects. While the concept is scientifically sound, it's essential to recognize that most peptides being used clinically have not completed rigorous FDA-approval processes, and much of our understanding comes from preclinical (animal) studies or small, uncontrolled human observations.
The Foundation Comes First: When Peptides Might Be Appropriate
Before I would even entertain a conversation about peptides with a perimenopausal patient, we must have addressed the fundamentals. This is non-negotiable. Peptides are not meant to compensate for gaps in foundational care; they're meant to potentially augment an already optimized system.
The prerequisites I require:
Hormonal Optimization: We've evaluated and, when appropriate, initiated hormone therapy (estrogen, progesterone, and testosterone as indicated). We've assessed thyroid function, cortisol patterns, and insulin sensitivity.
Nutritional Replenishment: We've identified and corrected deficiencies: iron, vitamin D, B12, magnesium, and other micronutrients that are commonly depleted in midlife women and essential for metabolic function.
Nervous System Regulation: We've addressed chronic stress, HPA axis dysregulation, and autonomic nervous system imbalance. This includes sleep optimization, stress reduction strategies, and appropriate treatment of anxiety or depression.
Lifestyle Foundations: Consistent strength training (essential for preserving muscle mass and bone density in perimenopause), 7-8 hours of quality sleep, protein adequacy, and sustainable stress management practices are established and maintained.
Only when these foundations are solid—and the patient has demonstrated commitment to maintaining them—would I consider peptides as a potential adjunct to enhance what we've already built, not to replace the building itself.
In my practice, hormone therapy is a prerequisite to peptide therapy.
Peptides of Interest for Perimenopausal Women: An Evidence Review
Below, I'll review the peptides most commonly discussed for women in perimenopause, along with what the research actually shows—and doesn't show.
BPC-157 (Body Protection Compound-157)
What It Is
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein naturally found in human gastric juice. It has been extensively studied in preclinical models for its effects on tissue healing and cytoprotection.
What the Research Suggests
The preclinical evidence for BPC-157 is genuinely intriguing. Animal studies demonstrate accelerated healing of tendons, ligaments, muscles, and gastrointestinal tissue. It appears to work through multiple mechanisms, including enhanced angiogenesis (formation of new blood vessels), upregulation of growth hormone receptors, and modulation of nitric oxide pathways. A review in the Journal of Physiology and Pharmacology noted that BPC-157 exhibits "potent anti-inflammatory and wound-healing properties" with "no toxicity being reported" in animal models.
For perimenopausal women specifically, the potential applications include supporting recovery from exercise-induced muscle damage, addressing joint and tendon issues that often emerge in midlife, and potentially supporting gut health—a common concern during the hormonal transition.
The Critical Caveats
Here's where my physician caution must dominate: BPC-157 has extremely limited human data. A 2024 systematic review published in the American Journal of Sports Medicine concluded that "clinical data were limited, and in-human safety remains unknown." The FDA has classified BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmacies due to insufficient evidence of human safety. WADA has banned it under the S0 Unapproved Substances category.
Additionally, BPC-157's pro-angiogenic properties—while beneficial for healing—raise theoretical concerns about tumor growth. As one pharmaceutical review noted, "the activation of pro-migratory signals and pro-angiogenic factors by BPC-157 is a double-edged sword." No studies have proven that BPC-157 causes cancer, but the biological plausibility of this concern cannot be dismissed.
GHK-Cu (Copper Peptide)
What It Is
GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to copper ions. It was first isolated from human plasma and is found in various body fluids, including saliva and urine. Levels decline with age, which has prompted interest in supplementation.
What the Research Suggests
GHK-Cu has perhaps the most robust human evidence of the peptides discussed here, though still limited. A clinical trial published in the Journal of Aging Science examining 40 women aged 40-65 demonstrated that topical GHK-Cu applied twice daily for 8 weeks "reduced wrinkle volume by 55.8% and wrinkle depth by 32.8%." The peptide appears to stimulate collagen and elastin production, enhance wound healing, and provide antioxidant effects.
For perimenopausal women experiencing accelerated skin aging due to declining estrogen, GHK-Cu represents a scientifically plausible option—particularly in topical formulations where safety data is more established.
The Critical Caveats
While topical GHK-Cu appears relatively safe, injectable forms carry greater uncertainty. Long-term safety data are lacking, and as with other peptides affecting tissue remodeling, theoretical concerns about promoting abnormal cell growth exist.
CJC-1295 and Ipamorelin (Growth Hormone Secretagogues)
What They Are
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), while ipamorelin is a growth hormone secretagogue that mimics ghrelin. They're often used together because they work through complementary mechanisms—CJC-1295 provides sustained growth hormone release over days, while ipamorelin produces a more immediate effect.
What the Research Suggests
A 2006 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 "resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated." Mean growth hormone concentrations increased by 2- to 10-fold for 6 days or more after a single injection. Ipamorelin research has shown it selectively stimulates growth hormone release without affecting ACTH or cortisol—a unique advantage over other secretagogues.
For perimenopausal women experiencing declining growth hormone levels (which naturally decrease with age), these peptides theoretically could support improved body composition, enhanced recovery, better sleep quality, and skin health.
The Critical Caveats
This is where my concerns become most significant. The relationship between IGF-1 (insulin-like growth factor-1, which increases with growth hormone stimulation) and cancer risk is well-documented in the scientific literature. A review in Proceedings of the National Academy of Sciences noted that "multiple large case-control studies have reported positive associations between high circulating levels of IGF-I and risk for different types of cancer," including breast, colorectal, and prostate cancers.
The FDA warns that both CJC-1295 and ipamorelin carry risks of immunogenicity (triggering immune responses) and cardiovascular effects, including "increased heart rate and systemic vasodilatory reaction." One clinical trial of CJC-1295 was discontinued following a participant’s death, though the attending physician believed the event was "unrelated to treatment."
Neither CJC-1295 nor ipamorelin is FDA-approved. For women with personal or family histories of hormone-sensitive cancers, I would consider these peptides contraindicated until long-term safety data become available.
TB-500 (Thymosin Beta-4 Fragment)
What It Is
TB-500 is a synthetic version of the active region of thymosin beta-4, a naturally occurring protein found in nearly all human tissues. It plays crucial roles in cell migration, tissue regeneration, and inflammation modulation.
What the Research Suggests
Thymosin beta-4 has been studied for wound healing, cardiovascular repair, and reduction of inflammation. Research published in Expert Opinion on Biological Therapy describes it as a "multi-functional regenerative peptide" with applications in corneal healing, cardiac repair, and general tissue regeneration.
The Critical Caveats
TB-500 carries perhaps the most concerning cancer-related data of the peptides discussed. Research published in Cancer Biology & Therapy demonstrated that thymosin beta-4 "is overexpressed in human pancreatic cancer cells" and has been shown to "stimulate tumor growth and metastasis by induction of cell migration and vascular endothelial growth factor-mediated angiogenesis." Multiple studies have found thymosin beta-4 upregulated in various cancers, including colorectal, gastric, pancreatic, and non-small cell lung cancer.
TB-500 is not FDA-approved and is banned by WADA. While it may have legitimate therapeutic applications, the cancer-related concerns make me particularly cautious about recommending it, especially in perimenopausal women who already face age-related increases in cancer risk.
For perimenopausal women, peptides could theoretically support improved body composition, enhanced recovery, better sleep quality, and skin health.
A Frank Discussion About Cancer Risk
I cannot in good conscience discuss these peptides without directly addressing cancer concerns. Many peptides work by promoting angiogenesis (blood vessel formation), cell migration, and tissue growth—the same mechanisms that tumors exploit to grow and spread.
The evidence we must consider:
IGF-1 and Cancer: Epidemiological studies consistently associate higher IGF-1 levels with increased cancer risk. A consensus statement from the Growth Hormone Research Society acknowledges that "preclinical data suggest that GH/IGF-I is involved in cancer development."
Angiogenesis Concerns: The VEGF/VEGFR2 pathways activated by BPC-157 and other peptides are "active in roughly half of human cancers." While promoting blood vessel formation is beneficial for healing, it's concerning in the context of potential tumor growth.
Lack of Long-Term Data: We simply don't have long-term human safety data for most of these peptides. Cancer can take years or decades to develop. The absence of evidence of harm is not evidence of safety.
It's important to note that no study has definitively proven these peptides cause cancer in humans. Some research even suggests certain peptides may have anti-tumor properties in specific contexts. However, the biological plausibility of risk, combined with the lack of long-term human data, demands caution.
Who Should NOT Consider Peptides
Based on current evidence, I would advise against peptide use in the following individuals:
Anyone with a current or recent cancer diagnosis
Anyone with a strong family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate, colorectal)
Anyone with genetic mutations predisposing to cancer (BRCA1/2, Lynch syndrome, etc.)
Anyone with active autoimmune disease or severe inflammatory conditions
Pregnant or breastfeeding women
Anyone who has not established foundational health practices
Competitive athletes (most peptides are banned substances)
Anyone seeking a "quick fix" rather than commitment to comprehensive health optimization
Peptides are not appropriate for everyone.
If Considering Peptides: A Cautious Approach
For patients who have established solid foundations, have no contraindications, understand the limitations of current evidence, and wish to explore peptides as a potential adjunct, here is the approach I might consider—with significant caveats:
Lower-Risk Starting Point
Topical GHK-Cu: This has the most established safety profile and documented benefits for skin health. Starting with topical application represents a conservative entry point.
Moderate Consideration (After Evaluation)
BPC-157: For patients with specific soft tissue healing needs or GI concerns, and after careful discussion of limited human data and theoretical risks. Would require sourcing from a reputable compounding pharmacy with appropriate testing.
Higher Caution (Individualized Decision)
CJC-1295/Ipamorelin: Only for carefully selected patients without cancer risk factors, with comprehensive informed consent about IGF-1-related concerns, and with regular monitoring. I would require baseline IGF-1 levels and periodic reassessment.
I would not currently recommend TB-500 given the concerning data regarding thymosin beta-4's association with tumor progression in multiple cancer types.
Topical GHK-Cu has the most established safety profile and documented benefits for skin health.
The Bottom Line
As I navigate this space with my patients, I hold two truths simultaneously: the preclinical evidence for certain peptides is genuinely compelling, AND the lack of rigorous human safety data demands significant caution.
The hype surrounding peptides in wellness circles often outpaces the evidence. Claims of dramatic transformations and minimal risks don't align with what the published literature supports. At the same time, dismissing these compounds entirely ignores legitimate scientific inquiry.
My approach is this: foundation first, always. Hormone optimization, nutritional replenishment, nervous system regulation, and lifestyle practices aren't just prerequisites—they're where the majority of results will come from. Peptides, if ever appropriate, are about potentially enhancing an already optimized system, not compensating for foundational gaps.
If you're curious about peptides, I encourage you to bring questions to a physician who can evaluate your individual situation, discuss risks and benefits honestly, and ensure you're not bypassing the fundamentals that will truly transform your health in perimenopause and beyond.
Disclaimer
This blog is for educational purposes only and does not constitute medical advice. Most peptides discussed are not FDA-approved for human use and carry unknown risks. Any decision to use peptides should be made in consultation with a qualified healthcare provider who can evaluate your individual health status, risks, and goals. Nothing in this article should be construed as an endorsement or recommendation for peptide use.
If you’re looking for professional-grade supplements you can trust, visit Dr. Bonza’s Fullscript dispensary and receive 10% off all supplements.
References
1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
2. Pollak M. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2004;3(4):S1-S7. PMC4164051
3. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822
4. Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci. 2016;4:166. https://doi.org/10.4172/2329-8847.1000166
5. Sikiric P, et al. Toxicity by NSAIDs: Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. PMID: 22950504
6. Zhang Y, et al. Thymosin Beta 4 is overexpressed in human pancreatic cancer cells. Cancer Biol Ther. 2008;7(3):419-23. PMC2930015
7. Chang CH, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. J Mol Med. 2017;95(3):323-333. PMID: 27847966
8. Deodati A, et al. Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis. Growth Horm IGF Res. 2014;24(4):105-11. PMID: 24818783
9. Boguszewska-Czubara A, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Am J Sports Med. 2024. PMC12313605
10. FDA Category 2 Bulk Drug Substances Nomination Review: BPC-157. U.S. Food and Drug Administration. 2023. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks